| 臺大學術典藏 |
2021-04-27T08:11:51Z |
The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia
|
HUNG-YANG KUO; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Hsu C.; Cheng W.-F.; Cheng A.-L.; Yang J.C.H.; Lai M.-S. |
| 臺大學術典藏 |
2021-04-26T01:47:25Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; MING-CHIH HO; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2021-04-22T06:56:51Z |
Low-dose thalidomide treatment for advanced hepatocellular carcinoma
|
Hsu C.; Chen C.-N.; Chen L.-T.; Wu C.-Y.; PEI-MING YANG; Lai M.-Y.; Lee P.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-29T06:37:04Z |
Critical Trio Exome Benefits In-Time Decision-Making for Pediatric Patients with Severe Illnesses?
|
Wu, E.-T.; Hwu, W.-L.; Chien, Y.-H.; Hsu, C.; Chen, T.-F.; Chen, N.-Q.; Chou, H.-C.; Tsao, P.-N.; Fan, P.-C.; Tsai, I.-J.; Lin, S.-P.; Hsieh, W.-S.; Chang, T.-M.; Chen, C.-N.; Lee, C.-H.; Chou, Y.-Y.; Chiu, P.-C.; Tsai, W.-H.; Hsiung, H.-C.; Lai, F.; Lee, N.-C.; FEI-PEI LAI |
| 臺大學術典藏 |
2021-03-19T06:57:53Z |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
Lin Z.-Z.; Hsu C.; YEUN-CHUNG CHANG; Yu C.-J.; Hsu C.-H.; Lin C.-C.; Cheng A.-L.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2021-03-19T01:54:20Z |
Considerations of heterogeneity in clinical trials for hepatocellular carcinoma
|
TSUNG-HAO LIU; Shao Y.-Y.; Lu L.-C.; Shen Y.-C.; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-19T01:54:19Z |
Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma
|
Shao Y.-Y.; TSUNG-HAO LIU; Hsu C.; Lu L.-C.; Shen Y.-C.; Lin Z.-Z.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-19T01:54:19Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Lu L.-C.; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; TSUNG-HAO LIU; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-19T01:54:18Z |
Novel systemic therapy for hepatocellular carcinoma
|
Dong Y.; TSUNG-HAO LIU; Yau T.; Hsu C. |
| 臺大學術典藏 |
2021-03-18T08:54:39Z |
Diagnostic value of 18F-FDG-PET/CT in indeterminate infiltrative hepatic lesions in an endemic area of viral hepatitis
|
Cheng M.-F.; YEN-WEN WU; Liu K.-L.; Yen R.-F.; Wu Y.-M.; Hsu C.; Chang Y.-T.; Tzen K.-Y.; Wang H.-P. |
| 臺大學術典藏 |
2021-03-18T05:59:10Z |
Diagnostic value of 18F-FDG-PET/CT in indeterminate infiltrative hepatic lesions in an endemic area of viral hepatitis
|
Cheng M.-F.; Wu Y.-W.; Liu K.-L.; Yen R.-F.; Wu Y.-M.; Hsu C.; Chang Y.-T.; KAI-YUAN TZEN; Wang H.-P. |
| 臺大學術典藏 |
2021-03-18T03:23:39Z |
The first two lines of chemotherapy for anthracycline-naive metastatic breast cancer: A comparative study of the efficacy of anthracyclines and non-anthracyclines
|
WEI-WU CHEN; Chang D.-Y.; Huang S.-M.; Lin C.-H.; Hsu C.; Lin M.-H.; Huang C.-S.; Lu Y.-S.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-18T03:23:29Z |
Spectrum of cancer patients receiving renal biopsy
|
Chang F.-C.; WEI-WU CHEN; Huang T.T.-M.; Lin W.-C.; Liu J.-S.; Chiang W.-C.; Chen Y.-M.; Hsu C.; Yeh K.-H.; Chu T.-S. |
| 臺大學術典藏 |
2021-03-18T02:02:48Z |
Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study
|
Hsu C.-H.;Kang Y.K.;Yang T.-S.;Chia-Tung Shun;Shao Y.-Y.;Su W.-C.;Sandoval-Tan J.;Chiou T.-J.;Jin K.;Hsu C.;Cheng A.-L.; Hsu C.-H.; Kang Y.K.; Yang T.-S.; CHIA-TUNG SHUN; Shao Y.-Y.; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-15T07:44:49Z |
Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer
|
LI-CHUN LU; Shao Y.-Y.; Hsu C.-H.; Hsu C.; Cheng W.-F.; Lin Y.-L.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2021-03-15T07:44:49Z |
Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems
|
Shao Y.-Y.; LI-CHUN LU; Lin Z.-Z.; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-15T07:44:46Z |
Tumor heterogeneity in hepatocellular carcinoma: Facing the challenges
|
LI-CHUN LU; Hsu C.-H.; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-15T07:44:44Z |
Considerations of heterogeneity in clinical trials for hepatocellular carcinoma
|
Liu T.-H.;Shao Y.-Y.;Li-Chun Lu;Shen Y.-C.;Hsu C.;Lin Z.-Z.;Hsu C.-H.;Cheng A.-L.; Liu T.-H.; Shao Y.-Y.; LI-CHUN LU; Shen Y.-C.; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-15T07:44:43Z |
Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma
|
Shao Y.-Y.;Liu T.-H.;Hsu C.;Li-Chun Lu;Shen Y.-C.;Lin Z.-Z.;Cheng A.-L.;Hsu C.-H.; Shao Y.-Y.; Liu T.-H.; Hsu C.; LI-CHUN LU; Shen Y.-C.; Lin Z.-Z.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-15T07:44:43Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Li-Chun Lu;Hsu C.;Shao Y.-Y.;Chao Y.;Yen C.-J.;Shih I.-L.;Hung Y.-P.;Chang C.-J.;Shen Y.-C.;Guo J.-C.;Liu T.-H.;Hsu C.-H.;Cheng A.-L.; LI-CHUN LU; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; Liu T.-H.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-15T06:27:34Z |
Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy
|
Lin Z.-Z.; Hsu C.; Hu F.-C.; Shao Y.-Y.; DWANG-YING CHANG; Yang C.-H.; Hong R.-L.; Hsu C.-H.; Chengb A.-L. |
| 臺大學術典藏 |
2021-03-15T06:27:33Z |
The first two lines of chemotherapy for anthracycline-naive metastatic breast cancer: A comparative study of the efficacy of anthracyclines and non-anthracyclines
|
Chen W.-W.; DWANG-YING CHANG; Huang S.-M.; Lin C.-H.; Hsu C.; Lin M.-H.; Huang C.-S.; Lu Y.-S.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-12T00:51:01Z |
Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer
|
Chang Y.-T.;Chang M.-C.;Wei S.-C.;Tien Y.-W.;Hsu C.;Liang P.-C.;Tsao P.-N.;I-Shiow Jan;Wong J.-M.; Chang Y.-T.; Chang M.-C.; Wei S.-C.; Tien Y.-W.; Hsu C.; Liang P.-C.; Tsao P.-N.; I-SHIOW JAN; Wong J.-M. |
| 臺大學術典藏 |
2021-03-09T06:46:18Z |
MVP (mitomycin-C, vinblastine, cisplatin) salvage chemotherapy for relapsed and refractory metastatic breast cancer
|
Hsu C.;Yeh K.-H.;Ruey-Long Hong;Yang C.-H.;Lin M.-T.;Chen Y.-C.;Cheng A.-L.; Hsu C.; Yeh K.-H.; RUEY-LONG HONG; Yang C.-H.; Lin M.-T.; Chen Y.-C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T06:46:11Z |
Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate
|
Lin C.-H.;Yen R.-F.;Jeng Y.-M.;Tzen C.-Y.;Hsu C.;Ruey-Long Hong; Lin C.-H.; Yen R.-F.; Jeng Y.-M.; Tzen C.-Y.; Hsu C.; RUEY-LONG HONG |
